ES2186790T3 - Formulacion de d-treo-metilfenidato de liberacion prolongada. - Google Patents

Formulacion de d-treo-metilfenidato de liberacion prolongada.

Info

Publication number
ES2186790T3
ES2186790T3 ES96924083T ES96924083T ES2186790T3 ES 2186790 T3 ES2186790 T3 ES 2186790T3 ES 96924083 T ES96924083 T ES 96924083T ES 96924083 T ES96924083 T ES 96924083T ES 2186790 T3 ES2186790 T3 ES 2186790T3
Authority
ES
Spain
Prior art keywords
methylphenidate
treo
formulation
prolonged release
prolonged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96924083T
Other languages
English (en)
Spanish (es)
Inventor
Helen Frances Baker
Julian Clive Gilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Application granted granted Critical
Publication of ES2186790T3 publication Critical patent/ES2186790T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
ES96924083T 1995-07-14 1996-07-15 Formulacion de d-treo-metilfenidato de liberacion prolongada. Expired - Lifetime ES2186790T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514451.5A GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation

Publications (1)

Publication Number Publication Date
ES2186790T3 true ES2186790T3 (es) 2003-05-16

Family

ID=10777685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96924083T Expired - Lifetime ES2186790T3 (es) 1995-07-14 1996-07-15 Formulacion de d-treo-metilfenidato de liberacion prolongada.

Country Status (17)

Country Link
US (1) US5874090A (2)
EP (1) EP0841928B1 (2)
JP (1) JPH11509228A (2)
KR (1) KR100481416B1 (2)
AT (1) ATE224715T1 (2)
AU (1) AU702371B2 (2)
CA (1) CA2223643C (2)
CZ (1) CZ285956B6 (2)
DE (1) DE69623970T2 (2)
DK (1) DK0841928T3 (2)
ES (1) ES2186790T3 (2)
GB (1) GB9514451D0 (2)
HU (1) HU224314B1 (2)
MX (1) MX9800394A (2)
PT (1) PT841928E (2)
SK (1) SK281569B6 (2)
WO (1) WO1997003673A1 (2)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP0840610A1 (en) 1995-07-14 1998-05-13 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US7553478B2 (en) * 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP3856283B2 (ja) * 2000-02-14 2006-12-13 シャープ株式会社 固体撮像装置および撮像装置の駆動方法
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
EP1163907B1 (en) * 2000-06-17 2006-04-12 Pharmaquest Limited Use of l-threo-methylphenidate for the manufacture of a medicament for the treatment of depression
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US6638533B2 (en) 2002-01-03 2003-10-28 George Krsek Pulse dosage formulations of methylphenidate and method to prepare same
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
JP2008523097A (ja) * 2004-12-09 2008-07-03 セルジーン・コーポレーション Ｄ−トレオメチルフェニデートを用いた治療
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
JP2008535922A (ja) * 2005-04-12 2008-09-04 エラン・ファルマ・インターナショナル・リミテッド 細菌感染を治療するためのセファロスポリンを含む放出制御組成物
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US8709477B2 (en) * 2009-08-13 2014-04-29 Kremers Urban Pharmaceuticals, Inc` Pharmaceutical dosage form
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt) 2011-03-23 2022-01-11 Ironshore Pharmaceuticals & Development, Inc Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
AU2013302657B2 (en) 2012-08-15 2018-08-09 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
KR102174787B1 (ko) 2018-11-14 2020-11-05 호서대학교 산학협력단 재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) * 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
DE69623970T2 (de) 2003-06-05
JPH11509228A (ja) 1999-08-17
GB9514451D0 (en) 1995-09-13
SK281569B6 (sk) 2001-05-10
DE69623970D1 (de) 2002-10-31
CA2223643A1 (en) 1997-02-06
EP0841928A1 (en) 1998-05-20
WO1997003673A1 (en) 1997-02-06
DK0841928T3 (da) 2003-01-27
SK2998A3 (en) 1998-07-08
AU6466196A (en) 1997-02-18
KR19990028984A (ko) 1999-04-15
HU224314B1 (hu) 2005-07-28
AU702371B2 (en) 1999-02-18
MX9800394A (es) 1998-09-30
KR100481416B1 (ko) 2005-07-29
EP0841928B1 (en) 2002-09-25
ATE224715T1 (de) 2002-10-15
CA2223643C (en) 2003-12-23
US5874090A (en) 1999-02-23
HUP9802252A3 (en) 1999-04-28
CZ9298A3 (cs) 1998-06-17
CZ285956B6 (cs) 1999-12-15
HUP9802252A2 (hu) 1999-01-28
PT841928E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
MX9800394A (es) Formulacion de liberacion sostenida de d-treo-metilfenidato.
HN1997000135A (es) Lactamas e imidas heterociclicas de aralguilo y aralguilideno
MX203891B (es) Compuestos funcionales de 1, 3-dicetoamida etilenicamente insaturados, polimeros de los mismos y formulaciones de latex que contienen los mismos
HN1998000011A (es) Derivados de acidos arilsulfonilaminohidroxamicos
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
FI955812L (fi) Siirrettävän tiedon koostumuksen säilyttäminen tukiaseman vaihdon yhteydessä
HN1998000036A (es) Compuesto de pirazina
CO4750664A1 (es) Marcfortinas y parahercuamidas antiparasitarias
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
AU4996096A (en) Retrieval of hyperlinked information resources using heuristics
HN1997000099A (es) Inhibidores de metaloproteasas matriciales basados en
HN1995009160A (es) Derivados de cicloalcano indol y azaindol
ATE206877T1 (de) Fluorierte kasein-mizellen
EP0677036A4 (en) PRODUCTION OF ODOR-FREE TETRAHYDROISOCUMULATES.
ES2138247T3 (es) Composicion y uso.
MX9203768A (es) Inhibidores novedosos de reductasa 3-hidroxi-metilglutaril-coenzima a.
AU8350698A (en) Metalloproteinase inhibitors
BR9906519A (pt) Conjunto de embreagem
CA2264626A1 (en) Pharmaceutical composition containing lornoxicam and a disodium salt of edta
EP0761808A3 (de) Verwendung substituierter Lactone als Riechstoffe
NO975582L (no) Fremgangsmåte for syntese av benzo£b|tiofener
ES2183368T3 (es) Composicion de higiene bucal que comprende una pululanasa de bacillus y una dextranasa.
ES2149353T3 (es) Polimorfos a y b de 1-(difenilmetil)-4-(3-(2-fenil-1,3-dioxolan-2-il)propil)piperazina.
TR199801087T2 (xx) 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il
JO1847B1 (en) Steam insulated cooker